Taiwan-based Bora Pharmaceuticals plans to add further sterile fill/finish capacity at its facility in Baltimore, MD. Installation of a new AST GENiSYS® C automated vial, syringe, and cartridge line will take place over the course of the next year. The new line will operate under full isolator conditions and is suited for clinical and small-scale commercial supply for high-value substances, according to J.D. Mowery, president of Bora’s CDMO division.
“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” added Mowery. “The addition of a precision small-scale isolator line adds to our overall capacity, and working in concert with our existing large-scale lines, increases our flexibility and scalability.”
![Installation of a new AST GENiSYS® C automated vial, syringe, and cartridge line will take place over the course of the next year at Bora’s Baltimore facility. [Bora Pharmaceuticals]](https://www.genengnews.com/wp-content/uploads/2025/06/GENiSYSCi-300x200.jpg)
Bora’s 87,000-ft2 Baltimore facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services for vials and pre-filled syringes on four fill lines. This is in addition to lyophilization, terminal sterilization, analytical, stability, packaging and serialization, and additional support services, continued Mowery. Earlier this year, Tanvex BioPharma completed its acquisition of Bora Biologics, a subsidiary of Bora Pharmaceuticals. Tanvex’s CDMO services operate under the name Bora Biologics.
